|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Erridge SC, Møller H, Price A and Brewster
D: International comparisons of survival from lung cancer: Pitfalls
and warnings. Nat Clin Pract Oncol. 4:570–577. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jego G, Hazoumé A, Seigneuric R and
Garrido C: Targeting heat shock proteins in cancer. Cancer Lett.
332:275–285. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ritossa F: Discovery of the heat shock
response. Cell Stress Chaperones. 1:97–98. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wen W, Liu W, Shao Y and Chen L:
VER-155008, a small molecule inhibitor of HSP70 with potent
anti-cancer activity on lung cancer cell lines. Exp Biol Med
(Maywood). 239:638–645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Phillips PA, Dudeja V, McCarroll JA,
Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM and Saluja AK:
Triptolide induces pancreatic cancer cell death via inhibition of
heat shock protein 70. Cancer Res. 67:9407–9416. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suzuki K, Ito Y, Wakai K, Kawado M,
Hashimoto S, Seki N, Ando M, Nishino Y, Kondo T, Watanabe Y, et al:
Serum heat shock protein 70 levels and lung cancer risk: A
case-control study nested in a large cohort study. Cancer Epidemiol
Biomarkers Prev. 15:1733–1737. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang Q, Zu Y, Fu X and Wu T: Expression
of heat shock protein 70 and 27 in non-small cell lung cancer and
its clinical significance. J Huazhong Univ Sci Technolog Med Sci.
25:693–695. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhuang H, Jiang W, Zhang X, Qiu F, Gan Z,
Cheng W, Zhang J, Guan S, Tang B, Huang Q, et al: Suppression of
HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced
apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L
expressions. J Mol Med (Berl). 91:219–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Leu JI, Pimkina J, Frank A, Murphy ME and
George DL: A small molecule inhibitor of inducible heat shock
protein 70. Mol Cell. 36:15–27. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leu JI, Pimkina J, Pandey P, Murphy ME and
George DL: HSP70 inhibition by the small-molecule
2-phenylethynesulfonamide impairs protein clearance pathways in
tumor cells. Mol Cancer Res. 9:936–947. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Granato M, Lacconi V, Peddis M, Lotti LV,
Di Renzo L, Gonnella R, Santarelli R, Trivedi P, Frati L, D'Orazi
G, et al: HSP70 inhibition by 2-phenylethynesulfonamide induces
lysosomal cathepsin D release and immunogenic cell death in primary
effusion lymphoma. Cell Death Dis. 4:e7302013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma L, Sato F, Sato R, Matsubara T, Hirai
K, Yamasaki M, Shin T, Shimada T, Nomura T, Mori K, et al: Dual
targeting of heat shock proteins 90 and 70 promotes cell death and
enhances the anticancer effect of chemotherapeutic agents in
bladder cancer. Oncol Rep. 31:2482–2492. 2014.PubMed/NCBI
|
|
14
|
Kaiser M, Kühnl A, Reins J, Fischer S,
Ortiz-Tanchez J, Schlee C, Mochmann LH, Heesch S, Benlasfer O,
Hofmann WK, et al: Antileukemic activity of the HSP70 inhibitor
pifithrin-μ in acute leukemia. Blood Cancer J. 1:e282011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sekihara K, Harashima N, Tongu M, Tamaki
Y, Uchida N, Inomata T and Harada M: Pifithrin-μ, an inhibitor of
heat-shock protein 70, can increase the antitumor effects of
hyperthermia against human prostate cancer cells. PLoS One.
8:e787722013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi ES, Nam JS, Jung JY, Cho NP and Cho
SD: Modulation of specificity protein 1 by mithramycin A as a novel
therapeutic strategy for cervical cancer. Sci Rep. 4:71622014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hers I, Vincent EE and Tavaré JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang JM, He QY, Guo RX and Chang XJ:
Phosphorylated Akt overexpression and loss of PTEN expression in
non-small cell lung cancer confers poor prognosis. Lung Cancer.
51:181–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Walczak H, Miller RE, Ariail K, Gliniak B,
Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sprick MR, Weigand MA, Rieser E, Rauch CT,
Juo P, Blenis J, Krammer PH and Walczak H: FADD/MORT1 and caspase-8
are recruited to TRAIL receptors 1 and 2 and are essential for
apoptosis mediated by TRAIL receptor 2. Immunity. 12:599–609. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chan KC, Ting CM, Chan PS, Lo MC, Lo KW,
Curry JE, Smyth T, Lee AW, Ng WT, Tsao GS, et al: A novel Hsp90
inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal
carcinoma cells and suppresses tumor formation. Mol Cancer.
12:1282013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen W, Sin SH, Wen KW, Damania B and
Dittmer DP: Hsp90 inhibitors are efficacious against Kaposi sarcoma
by enhancing the degradation of the essential viral gene LANA, of
the viral co-receptor EphA2 as well as other client proteins. PLoS
Pathog. 8:e10030482012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Li Z, Lin Z, Zhao B, Wang Y, Peng
R, Wang M, Lu C, Shi G and Shen Y: 17-DMCHAG, a new geldanamycin
derivative, inhibits prostate cancer cells through Hsp90 inhibition
and survivin downregulation. Cancer Lett. 362:83–96. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Baek SH, Ko JH, Lee JH, Kim C, Lee H, Nam
D, Lee J, Lee SG, Yang WM, Um JY, et al: Ginkgolic acid inhibits
invasion and migration and TGF-β-induced EMT of lung cancer cells
through PI3K/Akt/mTOR inactivation. J Cell Physiol. 232:346–354.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Monma H, Harashima N, Inao T, Okano S,
Tajima Y and Harada M: The HSP70 and autophagy inhibitor
pifithrin-μ enhances the antitumor effects of TRAIL on human
pancreatic cancer. Mol Cancer Ther. 12:341–351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ding X, Zhang B, Pei Q, Pan J, Huang S,
Yang Y, Zhu Z, Lv Y and Zou X: Triptolide induces apoptotic cell
death of human cholangiocarcinoma cells through inhibition of
myeloid cell leukemia-1. BMC Cancer. 14:2712014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Meng G, Wang W, Chai K, Yang S, Li F and
Jiang K: Combination treatment with triptolide and
hydroxycamptothecin synergistically enhances apoptosis in A549 lung
adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt
signaling pathways. Int J Oncol. 46:1007–1017. 2015.PubMed/NCBI
|
|
31
|
Zorzi E and Bonvini P: Inducible hsp70 in
the regulation of cancer cell survival: Analysis of chaperone
induction, expression and activity. Cancers (Basel). 3:3921–3956.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee SH, Lee EJ, Min KH, Hur GY, Lee SH,
Lee SY, Kim JH, Shin C, Shim JJ, In KH, et al: Quercetin enhances
chemosensitivity to gemcitabine in lung cancer cells by inhibiting
heat shock protein 70 expression. Clin Lung Cancer. 16:e235–e243.
2015. View Article : Google Scholar : PubMed/NCBI
|
